2 Information about nivolumab

2 Information about nivolumab

Marketing authorisation indication

Nivolumab (Opdivo; Bristol–Myers Squibb) has a marketing authorisation as 'monotherapy for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection'.

Dosage in the marketing authorisation

3 mg/kg nivolumab administered intravenously over 60 minutes every 2 weeks for up to 12 months.


£439 per 4‑ml vial; £1,097 per 10‑ml vial (excluding VAT; British national formulary [BNF] online [accessed August 2018]).

The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)